| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
MHC class I H-2Db molecules and cytotoxic T lymphocytes (CTLs). LCMV gp33-41 is a short peptide antigen fragment of LCMV glycoprotein that binds to MHC class I H-2Db molecules and is presented to CD8+ T cells, activating a specific cytotoxic immune response. The peptide is restricted to MHC class I H-2Db molecules, meaning it is only presented by cells expressing this specific MHC allele. The carboxyl-extended nature of the peptide (11 aa) enhances its MHC binding and T cell activation properties.
|
|---|---|
| ln Vitro |
In vitro, LCMV gp33-41 is used to stimulate LCMV-specific CD8+ T cells in T cell activation assays. The peptide binds to H-2Db MHC class I molecules and is recognized by TCRs on LCMV-specific CTLs, leading to T cell activation, proliferation, and cytokine production. It is commonly used in ELISPOT assays, intracellular cytokine staining (ICS), and tetramer staining to quantify antigen-specific T cell responses. The peptide's immunodominance makes it a valuable tool for studying T cell immunity and viral immunology.
|
| ln Vivo |
In vivo, LCMV gp33-41 is used in mouse models to study T cell responses to viral infection and vaccination. Administration of the peptide (typically with adjuvant) induces antigen-specific CD8+ T cell responses in H-2Db mice. The peptide is used in adoptive transfer experiments where LCMV-specific TCR transgenic T cells (such as P14 T cells) are transferred into recipient mice, followed by peptide immunization or LCMV infection to study T cell expansion, differentiation, and memory formation. It is also used in viral challenge models to evaluate protective immunity.
|
| Enzyme Assay |
In vitro peptide-MHC binding assays for LCMV gp33-41 measure the peptide's affinity for H-2Db MHC class I molecules. The assay uses purified H-2Db molecules (or cell lines expressing H-2Db) and fluorescently labeled reference peptides. Varying concentrations of LCMV gp33-41 are incubated with H-2Db molecules and beta2-microglobulin. After equilibration, bound peptide is detected by ELISA or fluorescence polarization. The peptide's binding affinity (IC50 or Kd) is calculated from competition curves. Alternatively, T2 cell lines (which lack TAP and load exogenous peptides onto MHC) are used to measure peptide-MHC stabilization by flow cytometry.
|
| Cell Assay |
In vitro T cell activation assays using LCMV gp33-41 are performed with splenocytes or purified CD8+ T cells from LCMV-immune or TCR transgenic mice. Cells are cultured with varying concentrations of the peptide (typically 0.001-10 microg/mL) for 2-6 hours in the presence of brefeldin A or monensin for cytokine detection. T cell activation is measured by intracellular cytokine staining (IFN-gamma, TNF-alpha, IL-2) followed by flow cytometry. Alternatively, ELISPOT assays are used to enumerate peptide-specific IFN-gamma-producing cells. CFSE dilution assays measure peptide-induced T cell proliferation after 3-5 days of culture.
|
| Animal Protocol |
In vivo mouse studies with LCMV gp33-41 are conducted in H-2Db mice (e.g., C57BL/6). For immunization, mice receive the peptide (typically 10-100 microg) emulsified in adjuvant (e.g., CFA, IFA, or CpG) via subcutaneous or intraperitoneal injection. For T cell tracking, LCMV-specific TCR transgenic T cells (P14 or SMARTA cells) are labeled with CFSE or a cell tracer and adoptively transferred into recipient mice. Mice are then immunized with peptide or infected with LCMV. Spleen and lymph nodes are harvested at various time points for flow cytometric analysis of T cell expansion, activation, and differentiation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of LCMV gp33-41 are characteristic of peptide antigens. With a molecular weight of 1044.22, the peptide is soluble in water. It is typically stored as a powder at -20degC for up to 3 years or in solution at -80degC for 1 year, protected from moisture. As a research peptide, pharmacokinetic studies are not typically performed as it is used as an antigen rather than a therapeutic agent. The peptide's stability and immunogenicity are the primary considerations in experimental design.
|
| Toxicity/Toxicokinetics |
Toxicological data for LCMV gp33-41 are not extensively documented as the peptide is used for research purposes only and not for therapeutic applications. As a short peptide antigen, it is generally well-tolerated in mouse studies at immunogenic doses. Standard safety precautions for handling peptides apply. The compound is intended for research use only and not for human therapeutic use. No significant toxicity has been reported in the literature for this research peptide.
|
| References | |
| Additional Infomation |
LCMV gp33-41 is a research-grade peptide antigen used in immunology and virology research. It is an H-2Db restricted epitope derived from LCMV glycoprotein gp33 (residues 33-41). The 11-amino-acid peptide sequence is Lys-Ala-Val-Tyr-Asn-Phe-Ala-Thr-Met (KAVYNFATM). It is presented to cytotoxic T lymphocytes by MHC class I H-2Db molecules. The peptide is widely used to study CD8+ T cell responses, viral immunity, and vaccine development. It is commonly used with P14 TCR transgenic T cells (specific for LCMV gp33-41/H-2Db) in adoptive transfer experiments. Not approved for clinical use.
|
| Molecular Formula |
C48H73N11O13S
|
|---|---|
| Molecular Weight |
1044.22413039207
|
| Exact Mass |
1043.511
|
| CAS # |
151705-84-9
|
| Related CAS # |
LCMV gp33-41 TFA
|
| PubChem CID |
5496744
|
| Appearance |
White to off-white solid powder
|
| LogP |
-3
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
32
|
| Heavy Atom Count |
73
|
| Complexity |
1850
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C(O)(=O)[C@H](CCSC)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)N
|
| InChi Key |
ZEDLVUSFPGQPJT-PGMHYMLFSA-N
|
| InChi Code |
InChI=1S/C48H73N11O13S/c1-25(2)38(58-40(63)26(3)52-42(65)32(50)14-10-11-20-49)46(69)57-35(23-30-15-17-31(61)18-16-30)44(67)56-36(24-37(51)62)45(68)55-34(22-29-12-8-7-9-13-29)43(66)53-27(4)41(64)59-39(28(5)60)47(70)54-33(48(71)72)19-21-73-6/h7-9,12-13,15-18,25-28,32-36,38-39,60-61H,10-11,14,19-24,49-50H2,1-6H3,(H2,51,62)(H,52,65)(H,53,66)(H,54,70)(H,55,68)(H,56,67)(H,57,69)(H,58,63)(H,59,64)(H,71,72)/t26-,27-,28+,32-,33-,34-,35-,36-,38-,39-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~12.5 mg/mL (~11.97 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9577 mL | 4.7883 mL | 9.5765 mL | |
| 5 mM | 0.1915 mL | 0.9577 mL | 1.9153 mL | |
| 10 mM | 0.0958 mL | 0.4788 mL | 0.9577 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
